SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Transition Therapeutics Inc. Announces Enrollment of the First Patient in Phase 2 Study of ELND005 (Scyllo-inositol) for the Treatment of Agitation/Aggression in Patients with Alzheimer's Disease
Your Message